Back to Stakeholders
Mindset PharmaCSE: MSET
1 Drug Candidate
Canadian drug discovery company focused on next-generation psilocybin and DMT analogues, acquired by Otsuka Pharmaceutical in October 2023 for approximately C$80 million. Lead compound MSP-1014, a novel psilocin prodrug, received MHRA approval for a Phase 2 clinical trial in the UK for major depressive disorder.
Drug Pipeline
1MSP-1014
Phase II
Novel psilocin prodrug. MHRA-approved Phase 2 clinical trial in the UK for major depressive disorder. Acquired by Otsuka Pharmaceutical October 2023.
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: MSET
- Lead Stage
- Phase II
- Acquired by
- Otsuka Pharmaceutical
- Website
- Visit